Malawi aims to provide 150,000 HIV-positive people with access to antiretrovirals

NewsGuard 100/100 Score

Malawi plans to provide 150,000 HIV-positive people with access to no-cost antiretroviral drugs by the end of the year, Biziwick Mwale, chief of the National AIDS Commission, said on Monday, AFP/Sunday Times reports.

According to Mwale, there already are about 110,000 people with antiretroviral access, and the goal is to expand that number to 150,000 by the end of December, when a "massive" drug treatment program is launched. The program will receive funding from the Global Fund To Fight AIDS, Tuberculosis and Malaria, according to AFP/Times.

If Malawi's treatment target is met, three-quarters of people in need of antiretrovirals will receive treatment access by the end of the year, Mwale said. "It's quite tremendous, and we are on course and superseding our overall (target) rates when we consider that we had less than 5,000 people on antiretrovirals in 2004," he added. The number of Malawians who receive voluntary HIV tests has increased to 500,000 annually from fewer than 50,000 three years ago, according to Mwale. He added that the biggest challenge to increasing access to antiretrovirals is the shortage of health care workers in the country. A recent survey by the Ministry of Health indicates that the country, which has a population of 12 million, employs 150 doctors.

According to UNAIDS estimates, there are about 930,000 people living with HIV/AIDS in Malawi, and approximately 78,000 AIDS-related deaths occur each year. The country's HIV prevalence is about 14% (AFP/Sunday Times, 7/9).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough study offers hope for an effective HIV cure